3D magnetic field guided sunflower-like nanocatalytic active swarm targeting patients-derived organoids
3D magnetic field guided sunflower-like nanocatalytic active swarm targeting patients-derived organoids
复制标题
3D 磁场引导向日葵状纳米催化活性群靶向患者来源的类器官
DOI：
10.1007/s12274-022-4851-z
复制
发表时间：
2022-09-12
期刊：
影响因子：
9.9
通讯作者：
Lu, Yuan
中科院分区：
文献类型：
--
作者：
Liu, Dong;Guo, Ruirui;Lu, Yuan
纳米催化药物引发原位催化反应被认为是一种有前途的肿瘤选择性治疗策略。然而，考虑到没有靶向推进能力，纳米催化剂的靶向分布仍然很低。在此，受快速发展的可控靶向递送微机器人的鼓舞，提出了由三维（3D）磁场控制的向日葵状纳米催化活性群（SNCAS），用于协同肿瘤选择性和磁活性肿瘤靶向治疗。此外，患者来源的肾癌细胞3D类器官用于验证有效的肿瘤治疗结果。在三维磁场的靶向控制下，评估了基于芬顿反应的SNCAS的多级联催化效率，导致高效的肿瘤细胞凋亡和死亡。对于患者来源的类器官治疗，SNCAS对3D类器官结构表现出显著的致死性，以诱导细胞凋亡，伴随类器官形态的崩溃。在SNCAS的磁控作用下，靶向效率进一步提高。总体而言，基于可控群的主动靶向与肿瘤特异性催化纳米药物协同治疗策略，在磁控技术的赋能下，为晚期肿瘤的治疗提供了一条新的途径。同时，3D患者源性类器官被证明是纳米催化药物有效性验证的有力工具。
Nanocatalytic medicine triggering in situ catalytic reactions has been considered as a promising strategy for tumor-selective therapeutics. However, the targeted distribution of nanocatalysts was still low, considering the absence of targeting propulsion capability. Here, encouraged by the fast-developing controllable microrobotics for targeting delivery, a sunflower-like nanocatalytic active swarm (SNCAS) controlled by a three-dimensional (3D) magnetic field was proposed for synergistic tumor-selective and magnetic-actively tumor-targeting therapeutics. Furthermore, a patient-derived renal cancer cell 3D organoid was utilized for the verification of the effective tumor therapeutic outcomes. Under the targeted control of 3D magnetic field, the multiple cascade catalytic efficiency of SNCAS based on Fenton reaction was evaluated, resulting in efficient tumor cell apoptosis and death. For the patient-derived organoid treatment, the SNCAS presented significant lethality toward 3D organoid structure to induce cell apoptosis with the collapse of organoid morphology. The targeting efficiency was further enhanced under the magnetic-controllable of SNCAS. Overall, empowered by the magnetic control technology, the synergistic therapeutic strategy based on controllable swarm combined active targeting and tumor-specific catalytic nanomedicine has provided a novel way for advanced cancer therapy. Meanwhile, 3D patient-derived organoids were proved as a powerful tool for the effectiveness verification of nanocatalytic medicine.